



Company Announcement no. 19/2008

To: OMX Nordic Exchange Copenhagen

Hørsholm, Denmark, April 17, 2008

LifeCycle Pharma A/S – Report Pursuant to the Danish Securities Trading Act, Section 28(a)

Hørsholm, Denmark, April 17, 2008; Pursuant to the Danish Securities Trading Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily basis, to make public transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons / companies closely associated with these.

Name	Dr. Thomas Dyrberg
Reason for reporting	Member of the Board of Directors
Issuer and ID code/ISIN	LifeCycle Pharma A/S / DK0060131043
Type of transaction	Purchase of shares
Date of transaction	April 15, 2008
Relevant market	OMX Nordic Exchange Copenhagen
Number of traded securities	6,600
Market value	DKK 112,200

Name	Dr. Michael Beckert
Reason for reporting	Chief Medical Officer & EVP
Issuer and ID code/ISIN	LifeCycle Pharma A/S / DK0060131043
Type of transaction	Purchase of shares
Date of transaction	April 15, 2008
Relevant market	OMX Nordic Exchange Copenhagen
Number of traded securities	20,000
Market value	DKK 340,000

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSHOLM
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 1 of 2



Name	Peter G. Nielsen
Reason for reporting	EVP Pharmaceutical Development and CMC
Issuer and ID code/ISIN	LifeCycle Pharma A/S / DK0060131043
Type of transaction	Purchase of shares
Date of transaction	April 15, 2008
Relevant market	OMX Nordic Exchange Copenhagen
Number of traded securities	1,000
Market value	DKK 17,000

About LifeCycle Pharma A/S (“LCP”)

LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose[®], LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, Fenoglide[™], currently on the U.S. market and a diversified near- and medium-term pipeline, including five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.

Contact:

LifeCycle Pharma A/S

Hans Christian Teisen

EVP and CFO

+45 2030 6985

HCT@lcpharma.com

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSBOLM
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 2 of 2